
Jennifer A. Pietenpol, Ph.D.
- Chief Scientific and Strategy Officer, VUMC
- Executive Vice President for Research, VUMC
- Brock Family Directorship in Career Development
- Professor of Biochemistry and Otolaryngology
Phone
652 Preston Research Building
Nashville, TN 37232-0146
Jennifer A. Pietenpol, Ph.D.
- Chief Scientific and Strategy Officer, VUMC
- Executive Vice President for Research, VUMC
- Brock Family Directorship in Career Development
- Professor of Biochemistry and Otolaryngology
615-936-1512
j.pietenpol@vumc.org
652 Preston Research Building
Nashville, TN 37232-0146
Research Program
Departments/Affiliations
Profile
Jennifer A. Pietenpol, Ph.D., is the Director of the Vanderbilt-Ingram Cancer Center, the Benjamin F. Byrd, Jr. Professor of Molecular Oncology, and Professor of Biochemistry and Otolaryngology. Pietenpol’s research focuses on breast cancer and the p53 family signaling network—the most frequently targeted network for mutation in human tumors. Recently, Pietenpol has integrated her research expertise in tumor suppressor genes and molecular genetics with bioinformatic analysis of high dimensional genomic data sets to molecularly subtype difficult-to-treat, triple negative breast cancer. Her results are being translated to clinical trials and alignment of patients to appropriate, molecularly targeted therapy. Her research has impacted many areas of science and medicine and she has translated her discoveries into clinical impact for breast cancer patients. Pietenpol’s research is funded by the National Cancer Institute, the Susan G. Komen for the Cure Foundation, and the Department of Defense Breast Cancer Program.
In 2008, the President appointed Pietenpol to a six-year term on the National Cancer Advisory Board. Also, Dr. Pietenpol serves on the external advisory boards for eight NCI Comprehensive Cancer Centers and leads two as Chair. In 2011, Pietenpol was appointed as member of the Susan G. Komen for the Cure Foundation Scientific Advisory Committee and as a member of the Frederick National Laboratory for Cancer Research Advisory Committee. Recently, Dr. Pietenpol completed a three-year, elected term on the AACR Board of Directors. This year she will begin a three-year term as a Member of the Institute of Medicine, National Cancer Policy Forum.
In 1997, Pietenpol received the Burroughs Wellcome New Investigator Award in Toxicology; in 2004, she was honored with the Excellence in Teaching Award at Vanderbilt for her mentoring of graduate and medical students. She was inducted into the Johns Hopkins Society of Scholars (2009) and received the Carleton College Distinguished Alumni Achievement Award in 2011. In 2012, she was elected as a fellow of the American Association for the Advancement of Science for outstanding contributions to the field of cancer research, particularly the involvement of signaling networks in breast and other cancers.
After graduating from Carleton with honors in biology and as a member of Sigma Xi, Pietenpol earned a Ph.D. in cell biology at Vanderbilt University School of Medicine in 1990. She continued her postgraduate training at Johns Hopkins Oncology Center (now Sidney Kimmel Comprehensive Cancer Center) before returning to Vanderbilt in 1995 as an assistant professor of biochemistry. She achieved the rank of full professor in 2002. Pietenpol has served as associate editor or on the editorial board for numerous biomedical research journals. She has authored or co-authored over 120 articles published in the peer-reviewed scientific literature.
Education
- Ph.D., Vanderbilt University, Nashville, Tennessee (1990)
- B.A., Carleton College, Northfield, Minnesota (1986)
Postdoctoral Training
- Fellowship, Johns Hopkins University (1994)
Research Emphasis
p53 family signaling axis (p53, p63, and p73); Breast Cancer; Triple-Negative Breast Cancer; Mechanisms of tumor suppression and epithelial cell differentiation
Research Description
The research program in the laboratory focuses on epithelial cancers, with a focus on triple-negative breast cancer and the p53 family-signaling network. The Pietenpol Lab pioneered techniques for analysis of p53-chromatin binding and identification of p53 target genes. They discovered that p63 signaling confers key epithelial differentiation properties to cells by regulating novel target genes and transcriptional programs. The group deciphered the functional p73 binding sites in the genome, was the first to link the mTOR signaling pathway to regulation of p73 activity and define a role for mTOR-p73 signaling in epithelial and mesenchymal differentiation. More recently, the laboratory has integrated expertise in molecular genetics with bioinformatics to molecularly subclassify difficult-to-treat, triple negative breast cancer into subtypes. The subtypes include basal-like (BL1, BL2), mesenchymal (M) and luminal androgen receptor (LAR). This work has been validated, and cited over 2,500 times since 2011. These results are being translated to clinical trials and alignment of patients to appropriate, molecularly targeted therapy.
Also, the Pietenpol laboratory made the seminal discovery that p73 is required for multiciliogenesis and regulates the FoxJ1-associated gene network; thus providing a unifying mechanism for many inflammation-mediated phenotypes observed in p73-knockout mice. The defects in multi-ciliated cell differentiation and immune signaling in the p73-deficient mice provide an animal model for the study of several human inflammatory diseases. Most recently, my team demonstrated that p73 is essential for ovarian folliculogenesis.
Publications
- Lehmann BD, Abramson VG, Sanders ME, Mayer EL, Haddad TC, Nanda R, Van Poznak C, Storniolo AM, Nangia JR, Gonzalez-Ericsson PI, Sanchez V, Johnson KN, Abramson RG, Chen SC, Shyr Y, Arteaga CL, Wolff AC, Pietenpol JA, . TBCRC 032 IB/II Multicenter Study: Molecular Insights to AR Antagonist and PI3K Inhibitor Efficacy in Patients with AR+ Metastatic Triple-Negative Breast Cancer. Clin Cancer Res [print-electronic]. 2020 May 5/1/2020; 26(9): 2111-23. PMID: 31822498, PMCID: PMC7196503, PII: 1078-0432.CCR-19-2170, DOI: 10.1158/1078-0432.CCR-19-2170, ISSN: 1078-0432.
- Schafer JM, Lehmann BD, Gonzalez-Ericsson PI, Marshall CB, Beeler JS, Redman LN, Jin H, Sanchez V, Stubbs MC, Scherle P, Johnson KN, Sheng Q, Roland JT, Bauer JA, Shyr Y, Chakravarthy B, Mobley BC, Hiebert SW, Balko JM, Sanders ME, Liu PCC, Pietenpol JA. Targeting MYCN-expressing triple-negative breast cancer with BET and MEK inhibitors. Sci Transl Med. 2020 Mar 3/11/2020; 12(534): PMID: 32161105, PMCID: PMC7427123, PII: 12/534/eaaw8275, DOI: 10.1126/scitranslmed.aaw8275, ISSN: 1946-6242.
- Lehmann BD, Shaver TM, Johnson DB, Li Z, Gonzalez-Ericsson PI, Sánchez V, Shyr Y, Sanders ME, Pietenpol JA. Identification of Targetable Recurrent MAP3K8 Rearrangements in Melanomas Lacking Known Driver Mutations. Mol Cancer Res [print-electronic]. 2019 Sep; 17(9): 1842-53. PMID: 31186280, PMCID: PMC6726520, PII: 1541-7786.MCR-19-0257, DOI: 10.1158/1541-7786.MCR-19-0257, ISSN: 1557-3125.
- Beeler JS, Marshall CB, Gonzalez-Ericsson PI, Shaver TM, Santos Guasch GL, Lea ST, Johnson KN, Jin H, Venters BJ, Sanders ME, Pietenpol JA. P73 regulates epidermal wound healing and induced keratinocyte programming. PLoS One. 2019; 14(6): e0218458. PMID: 31216312, PMCID: PMC6583996, PII: PONE-D-19-12187, DOI: 10.1371/journal.pone.0218458, ISSN: 1932-6203.
- Fuertes-Alvarez S, Maeso-Alonso L, Villoch-Fernandez J, Wildung M, Martin-Lopez M, Marshall C, Villena-Cortes AJ, Diez-Prieto I, Pietenpol JA, Tissir F, Lizé M, Marques MM, Marin MC. P73 regulates ependymal planar cell polarity by modulating actin and microtubule cytoskeleton. Cell Death Dis. 2018 Dec 12/5/2018; 9(12): 1183. PMID: 30518789, PMCID: PMC6281643, PII: 10.1038/s41419-018-1205-6, DOI: 10.1038/s41419-018-1205-6, ISSN: 2041-4889.
- Santos Guasch GL, Beeler JS, Marshall CB, Shaver TM, Sheng Q, Johnson KN, Boyd KL, Venters BJ, Cook RS, Pietenpol JA. P73 Is Required for Ovarian Follicle Development and Regulates a Gene Network Involved in Cell-to-Cell Adhesion. IScience [print-electronic]. 2018 Oct 10/26/2018; 8: 236-49. PMID: 30340069, PMCID: PMC6197761, PII: S2589-0042(18)30153-6, DOI: 10.1016/j.isci.2018.09.018, ISSN: 2589-0042.
- Jovanovic B, Mayer IA, Mayer EL, Abramson VG, Bardia A, Sanders ME, Kuba MG, Estrada MV, Beeler JS, Shaver TM, Johnson KC, Sanchez V, Rosenbluth JM, Dillon PM, Forero-Torres A, Chang JC, Meszoely IM, Grau AM, Lehmann BD, Shyr Y, Sheng Q, Chen SC, Arteaga CL, Pietenpol JA. A Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel With or Without Everolimus in Patients with Stage II/III Triple-Negative Breast Cancer (TNBC): Responses and Long-term Outcome Correlated with Increased Frequency of DNA Damage Response Gene Mutations, TNBC Subtype, AR Status, and Ki67. Clin. Cancer Res [print-electronic]. 2017 Aug 8/1/2017; 23(15): 4035-45. PMID: 28270498, PMCID: PMC5540799, PII: 1078-0432.CCR-16-3055, DOI: 10.1158/1078-0432.CCR-16-3055, ISSN: 1078-0432.
- Jovanovic B, Sheng Q, Seitz RS, Lawrence KD, Morris SW, Thomas LR, Hout DR, Schweitzer BL, Guo Y, Pietenpol JA, Lehmann BD. Comparison of triple-negative breast cancer molecular subtyping using RNA from matched fresh-frozen versus formalin-fixed paraffin-embedded tissue. BMC Cancer. 2017 Apr 4/4/2017; 17(1): 241. PMID: 28376728, PMCID: PMC5379658, PII: 10.1186/s12885-017-3237-1, DOI: 10.1186/s12885-017-3237-1, ISSN: 1471-2407.
- Cowen SD, Russell D, Dakin LA, Chen H, Larsen NA, Godin R, Throner S, Zheng X, Molina A, Wu J, Cheung T, Howard T, Garcia-Arenas R, Keen N, Pendleton CS, Pietenpol JA, Ferguson AD. Design, Synthesis, and Biological Activity of Substrate Competitive SMYD2 Inhibitors. J. Med. Chem [print-electronic]. 2016 Dec 12/22/2016; 59(24): 11079-97. PMID: 28002961, PII: 10.1021/acs.jmedchem.6b01303, ISSN: 1520-4804.
- Ludwik KA, Campbell JP, Li M, Li Y, Sandusky ZM, Pasic L, Sowder ME, Brenin DR, Pietenpol JA, O'Doherty GA, Lannigan DA. Development of a RSK Inhibitor as a Novel Therapy for Triple-Negative Breast Cancer. Mol. Cancer Ther [print-electronic]. 2016 Nov; 15(11): 2598-608. PMID: 27528706, PMCID: PMC5807013, PII: 1535-7163.MCT-16-0106, DOI: 10.1158/1535-7163.MCT-16-0106, ISSN: 1538-8514.